Home' Australian Pharmacist : Australian Pharmacist June 2016 Contents Australian Pharmacist June 2016 I ©Pharmaceutical Society of Australia Ltd.
Make the dream of becoming a doctor a reality, earn
your MD at Oceania University of Medicine.
n Attractive fee structure for our Graduate Entry Program.
n Over 150 students currently enrolled and over 50
graduates in Australia, New Zealand, Samoa and USA.
n Home-based Pre-Clinical Study under top international
medical school scholars, using world leading Pre-Clinical,
24/7 online delivery techniques.
n Clinical Rotations can be performed locally, Interstate or
n Receive personalised attention from an Academic Advisor.
n OUM Graduates are eligible to sit the AMC exam or NZREX.
OCEANIA UNIVERSITY OF MEDICINE
INTERNATIONALLY ACCREDITED For information visit www.oceaniamed.org or 1300 665 343
Applications now open for courses starting in January & July - No age restrictions
BPharm to MD
is allowing me
to realise my
Pharmacist from Cairns
Class of 2017
Ordering dose administration aids
(DAAs) will soon be easier than ever for
Fred users, with the release of DoseAid’s
exclusive new ordering software.
Developed by PractiCare, a leading
supplier of medication management
system solutions, myDoseAid integrates
seamlessly with Fred Dispense.
National Manager of DoseAid Seth
Grantley said the team was looking
forward to introducing its customers to
‘Now that our software is compatible
with Fred Dispense, customers will
be better placed to satisfy increased
demand for DAAs and leverage their
value for the benefit of their patients
and their business. Our customers asked
for an easy-to-use system that would
help improve efficiencies and in store
workflow – and we wanted to make sure
‘We are currently working on integrating
myDoseAid with other dispense systems,
so that all DoseAid customers can enjoy
the benefits it brings,’ Mr Grantley said
Eli Lilly’s drug Taltz (ixekizumab), which was recently approved by the FDA
for the treatment of adults with moderate-to-severe plaque psoriasis, is set
to generate sales in excess of $1 billion in the US and Europe by 2022 due
to its high clinical efficacy and good safety profile, according to research
and consulting firm GlobalData.
According to GlobalData’s report on
the psoriasis market, the last six years
have seen an influx of novel plaque
psoriasis treatments outside mainstay
anti-tumour necrosis factor (anti-TNF)
therapies. Novartis’ Cosentyx, the first-to
market interleukin-17A (IL-17A) inhibitor
launched in 2015, has shown superior
efficacy over other approved biologics,
most notably the anti-TNF therapy Enbrel.
GlobalData’s Analyst covering
Immunology Alexandra Annis, said: ‘Taltz
has a shared mechanism of action with
Cosentyx, and GlobalData anticipates it
could be used ahead of a TNF inhibitor
in biologic- and/or TNF-naïve patients
in the psoriasis space. Although it will
be competing with Cosentyx, which has
a significant first-to-market advantage,
Taltz offers more convenient dosing.
‘ The recommended dosing for Taltz is
an initial 160 mg subcutaneous (SC)
injection followed by an 80 mg SC
injection once every two weeks for
12 weeks, then 80 mg every four weeks.
In comparison, 300 mg of SC Cosentyx
is administered once a week, followed
by 300 mg every four weeks. In this way,
Taltz will hold an edge in the anti-IL-17A
market for psoriasis.’
In terms of competition GlobalData
believes Taltz may face within the anti-
IL17 class, Valeant’s brodalumab may
pose a threat, which is in pre-registration
in the US and Europe for plaque psoriasis.
Ms Annis said: ‘Although the drug has
garnered safety concerns recently
surrounding increased suicidal
tendencies, brodalumab demonstrated
clear superiority over Stelara in two
head-to-head clinical trials, AMAGINE-2
and AMAGINE-3, and established itself
as one of the most effective psoriasis
drugs developed to date.
‘Despite the competition, GlobalData
anticipates Taltz will become a
blockbuster therapy due to its
exceptionally high clinical efficacy.’
Links Archive Australian Pharmacist May 2016 Australian Pharmacist July 2016 Navigation Previous Page Next Page